Adial Pharmaceuticals Executive Matt Davidson Buys Shares

Matt Davidson, the Chief Development Officer at Adial Pharmaceuticals, Inc. (NasdaqCM: ADIL), recently purchased 232,417 shares of the company. This insider transaction, which took place on June 12, 2026, was not part of a pre-arranged trading plan.

Insider Buying and Selling at Adial Pharmaceuticals, Inc.

Several insiders at Adial Pharmaceuticals have been active in the market. On June 12, 2026, Matt Davidson acquired 232,417 shares, following a previous purchase of 65,074 shares on June 11, 2026. Wendy Young also bought 36,378 shares at $2.75 per share on June 12, 2026. Additionally, Cary Claiborne, the CEO, purchased 37,985 shares on April 7, 2026.

Other Institutional Activity in Adial Pharmaceuticals

Several institutional investors have adjusted their positions in Adial Pharmaceuticals. Geode Capital Management, LLC increased its holdings by 18,019 shares, bringing its total to 24,249 shares valued at about $43,405. Vanguard Fiduciary Trust Co added 5,879 shares, ending with the same number of shares worth approximately $10,523. Meanwhile, Manchester Capital Management LLC and BlackRock, Inc. slightly reduced their positions, each by 1 share.

Adial Pharmaceuticals Stock Snapshot

Shares of Adial Pharmaceuticals (NasdaqCM: ADIL) traded around $2.85. The company has a market cap of roughly $6.24 million. It is not currently profitable, reflected in its negative forward P/E ratio of -1.86. The stock's 52-week range is between $1.31 and $19.00, with a 50-day moving average of $1.87 and a 200-day moving average of $5.16. Adial maintains a current ratio of 3.18 and a quick ratio of 3.04, indicating strong liquidity.

Analysts Set New Price Targets

On June 15, 2026, Lucid Capital Markets initiated coverage on Adial Pharmaceuticals with a 'buy' rating and a price target of $6.00. This follows Maxim Group's upgrade to a 'buy' rating with a $1.50 target on September 30, 2025. The consensus among analysts is a 'buy', with a mean target price of $8.00 based on one analyst's opinion.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc. is a biotechnology company focused on developing treatments for addiction and related disorders. Their lead product, AD04, is a serotonin-3 antagonist currently in Phase 3 trials for alcohol use disorder. The company is also working on non-opioid pain reduction therapies. Founded in 2010, Adial is headquartered in Glen Allen, Virginia, and employs five people under the leadership of CEO Cary John Claiborne.

Bottom Line

Insider buying activity at Adial Pharmaceuticals, particularly by Chief Development Officer Matt Davidson, suggests confidence in the company's prospects. Adial, a small-cap biotech firm, is actively developing treatments for addiction, with its main product in Phase 3 trials. Investors should note that insider transactions are reported after they occur and may not reflect the current position of the insider.